Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Murepavadin in Nosocomial Pneumonia
NCT03582007Phase 3Terminated
- Sponsor
- Polyphor
- Start
- Oct 2018
- Primary completion
- Jul 2019
- Modality
- Modified Peptides
- Countries
- 4
01
Overview
A Phase 3 trial of murepavadin in hospital-acquired pneumonia (HAP), sponsored by Polyphor. Started Oct 2018; status: terminated.
02
Drugs
murepavadin
03
Conditions
hospital-acquired pneumonia (HAP)
Beyond the preview
Go deeper on NCT03582007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03582007.